IL-34 and Immune Checkpoint Inhibitors Resistant through Macrophages: Pan-Cancer Overview
Open Access
- 1 March 2023
- journal article
- letter
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 16, 1209-1212
Abstract
Discussing the utilization of immune checkpoint inhibitors (ICIs) to induce therapeutic anti-tumor activity as a promising strategy.Keywords
This publication has 8 references indexed in Scilit:
- Targeting IL-34/MCSF-1R Axis in Colon CancerFrontiers in Immunology, 2022
- A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistanceNature Immunology, 2022
- Interleukin-34 Limits the Therapeutic Effects of Immune Checkpoint BlockadeiScience, 2020
- Roles of IFN-γ in tumor progression and regression: a reviewBiomarker Research, 2020
- Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?American Society of Clinical Oncology Educational Book, 2019
- Macrophages as regulators of tumour immunity and immunotherapyNature Reviews Immunology, 2019
- Resistance to PD1/PDL1 checkpoint inhibitionCancer Treatment Reviews, 2017
- Chemotherapy-Induced IL34 Enhances Immunosuppression by Tumor-Associated Macrophages and Mediates Survival of Chemoresistant Lung Cancer CellsCancer Research, 2016